Posted On: 11/19/2014 5:47:01 PM
Post# of 30032
Exactly my thinking, Chris. This scenario explains everything about why there have been no revenue projections from the company, and why they haven't been promoting LymPro in the media like we've heard with other AD tests that are still years to market.
Yet we still have shareholders ranting about wanting to know LymPro revenue projections, and how we should be DEMANDING it from management. Perhaps some investors should stop over-thinking this and listen to the CC again, and forget what their prior expectations were regarding LymPro.
I believe Jason now understands, and I'll be surprised if he has any further comments on LymPro revenue, as his estimate was proven irrelevant by the company's plan for LymPro and the diagnostics division. I'm confident those who are considering the purchase have full knowledge of what the expected revenues are. Jason may have tossed out a lowball number to spur Gerald to counter with realistic projections. Now he understands why Gerald didn't respond.
Yet we still have shareholders ranting about wanting to know LymPro revenue projections, and how we should be DEMANDING it from management. Perhaps some investors should stop over-thinking this and listen to the CC again, and forget what their prior expectations were regarding LymPro.
I believe Jason now understands, and I'll be surprised if he has any further comments on LymPro revenue, as his estimate was proven irrelevant by the company's plan for LymPro and the diagnostics division. I'm confident those who are considering the purchase have full knowledge of what the expected revenues are. Jason may have tossed out a lowball number to spur Gerald to counter with realistic projections. Now he understands why Gerald didn't respond.
(0)
(0)Scroll down for more posts ▼
